Relevant bibliographies by topics / Antiasthmatic agents

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Antiasthmatic agents'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antiasthmatic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antiasthmatic agents"

1

Bianco, Sebastiano, Maria Grazia Pieroni, Rosa Metella Refini, Maria Robuschi, Adriano Vaghi, and Piersante Sestini. "Could NSAIDs Have a Role as Antiasthmatic Agents?" Drugs 48, no. 1 (July 1994): 9–15. http://dx.doi.org/10.2165/00003495-199448010-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rajizadeh, Mohammad Amin, Hamid Najafipour, and Mohammad Abbas Bejeshk. "An Updated Comprehensive Review of Plants and Herbal Compounds with Antiasthmatic Effect." Evidence-Based Complementary and Alternative Medicine 2024 (February 8, 2024): 1–36. http://dx.doi.org/10.1155/2024/5373117.

Full text
Abstract:
Background. Asthma is a common disease with rising prevalence worldwide, especially in industrialized countries. Current asthma therapy with traditional medicines lacks satisfactory success, hence the patients’ search for alternative and complementary treatments for their diseases. Researchers have conducted many studies on plants with antiallergic and antiasthmatic effects in recent decades. Many of these plants are now used in clinics, and searching for their mechanism of action may result in creating new ideas for producing more effective drugs. Purpose. The goal of this review was to provide a compilation of the findings on plants and their active agents with experimentally confirmed antiasthmatic effects. Study Design and Method. A literature search was conducted from 1986 to November 2023 in Scopus, Springer Link, EMBASE, Science Direct, PubMed, Google Scholar, and Web of Science to identify and report the accumulated knowledge on herbs and their compounds that may be effective in asthma treatment. Results. The results revealed that 58 plants and 32 herbal extracted compounds had antiasthmatic activity. Also, 32 plants were shown to have anti-inflammatory and antioxidative effects or may act as bronchodilators and potentially have antiasthmatic effects, which must be investigated in future studies. Conclusion. The ability of herbal medicine to improve asthma symptoms has been confirmed by clinical and preclinical studies, and such compounds may be used as a source for developing new antiasthmatic drugs. Moreover, this review suggests that many bioactive compounds have therapeutic potential against asthma.
APA, Harvard, Vancouver, ISO, and other styles
3

Prasad, M. Raghu, R. H. Bahekar, and A. R. R. Rao. "ChemInform Abstract: Recent Perspectives in the Design of Antiasthmatic Agents." ChemInform 31, no. 41 (October 10, 2000): no. http://dx.doi.org/10.1002/chin.200041272.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khah, Shaila, Rohit Goyal, Ankush Chabba, Varun Jaiswal, Gaurav Sharma, and Mu Naushad. "Certain 4-Iminoflavones Derivatives: Synthesis, Docking Studies, Antiasthmatic and Antimicrobial Agents." Asian Journal of Chemistry 28, no. 8 (2016): 1687–96. http://dx.doi.org/10.14233/ajchem.2016.19789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Anagnostopulos, Hiristo, Robert R. Bartlett, Ulrich Elben, and Paul Stoll. "Synthesis of basic substituted pyridines: a new class of antiasthmatic-antiallergic agents." European Journal of Medicinal Chemistry 24, no. 3 (May 1989): 227–32. http://dx.doi.org/10.1016/0223-5234(89)90003-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shringi, M., and C. Baregama. "1,3,7,8-SUBSTITUTED XANTHINE DERIVATIVES AS POTENTIAL ANTIASTHMATIC AGENTS WHICH ACT ON ADENOSINE RECEPTOR." INDIAN DRUGS 56, no. 07 (July 28, 2019): 84–87. http://dx.doi.org/10.53879/id.56.07.11436.

Full text
Abstract:
Asthma is one of the most common chronic diseases in modern society. There is a high prevalence of usage of complementary medicine for asthma. Xanthine derivatives which act on adenosine receptor have been cited as a most popular complementary treatment. This studys was undertaken to determine if there is any evidence for the clinical efficacy of xanthine derivatives for the treatment of asthma symptoms. This review highlights the more recent developments in the design and optimization of xanthine derivatives which act on A2A and A2B adenosine receptor. 1,3,8 and 1,3,7,8-substituted xanthine derivatives were found to be effetive. 1,3,7,8 Substituted xanthine derivative possess good affinity on A2A and A2B AR and are not selective for one particular receptor. This is benefitical for decreasing the side effects related to CVS.
APA, Harvard, Vancouver, ISO, and other styles
7

Gawali, U. P., and Anuradha deshkar. "PHARMACOVIGILANCE STUDY OF ANTIASTHMATIC AGENTS IN PATIENTS OF BRONCHIAL ASTHMA AT A TERTIARY CARE CENTRE." International Journal of Advanced Research 5, no. 3 (March 31, 2017): 1867–71. http://dx.doi.org/10.21474/ijar01/3703.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bhosale, Uma, Shruti Jaiswal, Radha Yegnanarayan, and Gouri Godbole. "A pharmacovigilance study of antiasthmatic agents in patients of bronchial asthma at a tertiary care hospital." Journal of Clinical & Experimental Research 1, no. 2 (2013): 26. http://dx.doi.org/10.5455/jcer.201322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

YAMAGUCHI, Masahisa, Noriaki MARUYAMA, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. V. Thienopyridazinone Derivatives." CHEMICAL & PHARMACEUTICAL BULLETIN 43, no. 2 (1995): 236–40. http://dx.doi.org/10.1248/cpb.43.236.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

YAMAGUCHI, Masahisa, Noriaki MARUYAMA, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. VI. Indazole Derivatives." CHEMICAL & PHARMACEUTICAL BULLETIN 43, no. 2 (1995): 332–34. http://dx.doi.org/10.1248/cpb.43.332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antiasthmatic agents"

1

Al-Wabel, Naser A. "Acute induction of tracheo-bronchoconstriction in morphine/chloralose anesthetized dogs physiological approach and principles of therapy /." Connect to this title online, 2003. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1069557474.

Full text
Abstract:
Thesis (Ph.D.)--Ohio State University, 2003.
Title from first page of PDF file. Document formatted into pages; contains xvii, 175 p.; also includes graphics (some col.). Includes abstract and vita. Advisor: Robert L. Hamlin, Dept.of Veterinary Biosciences. Includes bibliographical references (p. 159-175).
APA, Harvard, Vancouver, ISO, and other styles
2

Huang, Wenhua. "Investigation of semipermeable coated tablet and liposomal dry powder inhaler formulation of salbutamol sulfate." HKBU Institutional Repository, 2010. http://repository.hkbu.edu.hk/etd_ra/1159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Meeuwisse, Willem H. "The effect of salbutamol on performance in elite non-asthmatic athletes." Thesis, University of British Columbia, 1990. http://hdl.handle.net/2429/28769.

Full text
Abstract:
The effect of salbutamol on performance was studied in 7 male non-asthmatic elite (VO₂max ≥ 60 ml/kg/min) athletes. The subjects entered the study just prior to their competitive season. Salbutamol (2 puffs=200 µg) or placebo was administered by metered-dose inhaler, through a spacer device, 20 minutes prior to testing in a double-blind, randomized crossover design. Pulmonary functions including maximum flow volume curves were performed on the first two visits, at 5 intervals (pre-medication, 20 minutes post-medication, and 5, 10, and 20 minutes post-exercise). The first two sessions combined these pulmonary function measures with an exercise bout consisting of a continuously ramped cycle ergometer ride to exhaustion to determine maximal oxygen uptake (VO₂max), peak power, and maximal heart rate. Pulse oximetry was used to measure the oxygen saturation of hemoglobin. The next sessions involved performing a 45 minute ride at 70% of VO₂max, followed by a timed sprint to exhaustion. Lastly, a Wingate anaerobic test was used to measure total work and peak power. There was a non-significant decrease in VO₂max from a mean of 63.5 ml/kg/min (± 3.2) for the placebo (P) trial, to a mean of 62.6 (± 3.3) with salbutamol (S). No difference was found in peak power (P= 438 Watts ±26.3, S= 438 ±27.9) or maximum heart rate (P=191 beats/min ±5.4, S=191 ±6.0). The performance related variables of endurance sprint time (P=104 seconds ±22.8, S= 97 ±31.4), and Wingate peak power (P= 10.12 Watts/kg ±0.57, S= 9.97 ±0.60) showed a non-significant decrease, while the total work performed on the Wingate test (P= 19.30 kJ ±2.09, S= 19.61 ±1.54) displayed a non-significant increase. The data failed to show significance despite using statistical analysis with a level of significance of p<0.20 to maximize the power of the tests. There was a statistically significant (p<0.05) increase in post medication (pre-exercise) forced expiratory volume (FEV₁) of 4.5% with salbutamol. This baseline increase persisted post-exercise, but there was no interaction effect of salbutamol and placebo over time. This represents an expected effect in non-asthmatic individuals, and although statistical significance was achieved, the magnitude of difference is not considered to be clinically significant. It was concluded that a therapeutic dose of aerosol salbutamol does not have an ergogenic effect in elite non-asthmatic athletes and it is therefore recommended that inhaled salbutamol continue to be permitted in international competition for individuals with exercise induced asthma.
Education, Faculty of
Curriculum and Pedagogy (EDCP), Department of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
4

Jacobson, GA. "Aspects of the pharmacotherapy of airways disease." Thesis, 1996. https://eprints.utas.edu.au/20358/7/whole_JacobsonGlennAndrew1997.pdf.

Full text
Abstract:
Asthma morbidity and mortality have been increasing in most industrialised countries over the last two decades despite anti-asthmatic medication sales at an all time high. Drug therapy remains the mainstay of treatment in asthma yet there have been concerns that modern drug therapy may be contributing to this increase in morbidity and mortality. The research presented in this thesis sought to examine several issues related to current asthma pharmacotherapy. In recent years, asthma management guidelines have emphasised the earlier introduction of inhaled corticosteroids and less reliance on β₂-agonists. The prescribing of anti-asthmatic drugs within Tasmania was examined from April 1991 to April 1994 using computerised dispensing records from nearly one-third of all the community pharmacies within the State. Trends in prescribing were compared with national data and regional State differences were examined. It was found that drug utilisation, both nationally and within Tasmania, appeared to be changing in line with current management guidelines with increases in inhaled corticosteroid and sodium cromoglycate usage while β₂-agonists usage remained fairly stable. There was a marked decrease in the ratio of β₂-agonists:inhaled corticosteroids dispensed over the period of the study. Nebulised ipratropium bromide (an anti-cholinergic drug) is often combined with nebulised agonists in the treatment of asthma and chronic obstructive airways disease. To reduce the time that patients spend inhaling nebulised drug ipratropium bromide is often mixed with β₂- agonists immediately prior to administration but is sometimes bulk mixed and stored for several days before use. A reversed-phase ion-pair assay wing UV detection was developed to study the stability of these bulk mixed nebuliser solutions. The stability of an admixture of proprietary ipratropium bromide and salbutamol nebuliser solution (1:1, v/v) was then examined for 5 days under different storage conditions. It was found that admixtures of ipratropium bromide and salbutamol nebuliser retain greater than 90% of their initial concentrations if stored at or below 22° C for periods of up to 5 days. Finally, an assay using solid-phase extraction was developed to measure urinary levels of salbutamol in a relatively large group of asthmatic patients using inhaled therapy. Salbutamol levels in 'spot' urine samples were investigated as a potential indicator of over-use. Median levels of unchanged drug were 378 ng/ml (range 0-34.4 μg/m1) and 2.55 tig/m1 (range 0- 49.8 μg/m1) in community and hospital patients respectively. Even when conceding the limitations of 'spot' urine sampling there were large inter-patient differences in levels corrected for dosage, probably due to differences in technique of administration and pharmacokinetic variability. There were also indications of possible low level saturation of metabolism which may have clinical implications.
APA, Harvard, Vancouver, ISO, and other styles
5

Kitching, Jacki Anne. "The development of new, non-steroidal anti-asthma drugs with novel modes of action." Phd thesis, 2008. http://hdl.handle.net/1885/151679.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antiasthmatic agents"

1

1946-, Barnes Peter J., ed. New drugs for asthma. London: IBC Technical Services, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

National Heart, Lung, and Blood Institute and American Association for Respiratory Care, eds. Making a difference in the management of asthma: A guide for respiratory therapists. [Bethesda, Md.]: U.S. Dept. of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Strobel, Martine. Asthma bronchiale: Die Geschichte seiner medikamentösen Therapie bis zum Beginn des 20. Jahrhunderts. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Frost & Sullivan., ed. European asthma treatment product markets: Shift in use of single-agent bronchodilation to combination drug therapy. Mountain View, Calif: Frost & Sullivan, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

F, D'Arcy P., and McElnay J. C. 1954-, eds. The Pharmacy and pharmacotherapy of asthma. Chichester: E. Horwood, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Clive, Wood, and Royal Society of Medicine (Great Britain), eds. Astemizole in asthma. London: Royal Society of Medicine Services, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sannes, Lucy J. Asthma: Current and emerging therapies and markets. Waltham, MA: Decision Resources, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Frost & Sullivan., ed. U.S. allergy and asthma treatment markets, update 3. Mountain View, Calif: Frost & Sullivan, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1962-, Anderson G. P., Chapman I. D. 1958-, Morley J. 1938-, and International Congressional of Pharmacology (11th : 1990 : Amsterdam, Netherlands), eds. New drugs for asthma therapy. Basel: Birkhäuser Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Inc, Medical Data International, ed. U.S. markets for respiratory care products. Irvine, Calif. (2 Park Palza, Suite 1200, Irvine 92614): Medical Data International, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antiasthmatic agents"

1

Shah, Neel Jayesh. "Screening Methods for the Evaluation of Antiasthmatic Agents." In Introduction to Basics of Pharmacology and Toxicology, 437–41. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-5343-9_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Christensen, Siegfried B., and Theodore J. Torphy. "Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents." In Annual Reports in Medicinal Chemistry, 185–94. Elsevier, 1994. http://dx.doi.org/10.1016/s0065-7743(08)60732-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dobhal, Kiran, Vikash Jakhmola, and Jaya Rautela. "Diversities of Omnipotent Tulsi: Pharmacological and Chemical Aspects." In The Chemistry inside Spices & Herbs: Research and Development, 152–72. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815196801124030008.

Full text
Abstract:
Ocimum is a well-known genus accepted for various ethnopharmacological benefits worldwide. The Tulsi plant is abundant globally; and falls under the Ocimum species. Earlier, numerous species relevant to the Ocimum genus have been identified and cultivated in various parts of the world. Leaves of Ocimum contain 0.1% of essential oils, which are composed of eugenol, citral, ursolic acid, carvacrol, linalool, limatrol, caryophyllene, camphor, and estragole while fatty acids and sitosterol are present in the volatile oil of seed. Eugenol is responsible for its potential effect. The ethnopharmacological aspects of Ocimum species have been reported as antimicrobial, antimalarial, anthelmintic, anti-mosquito agents, anti-diarrheal, anti-oxidant, anticataract, anti-inflammatory, chemo, and radioprotective, antiseptic drugs, cardioprotective, anti-diabetic, anti-hyperlipidemic, anti-hypertensive, anti-cancer, pain killer, antiallergenic, antidepressant, memory boosting drugs, antiasthmatic, cough suppressant, diaphoretic, anti-thyroid, anti-fertility, spasmolytic, anti-arthritic, herbal pharmaceuticals, anti-anxiety, and blood thinning activities. In the previous studies, Tulsi has reported the potential effect against cellular toxicity caused by insecticides and industrial chemicals, which is the subject of attention. In this chapter, the author will explore the pharmacological and chemical paradigms of Tulsi that are present globally.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antiasthmatic agents"

1

Milenina, Lidiya, Zoya Krutetskaya, Victor Antonov, Nina Krutetskaya, Valentina Badulina, and Armen Simonyan. "ANTIASTHMATIC AGENT ZILEUTON SUPPRESSES Ca2+ RESPONSES, INDUCED BY GLUTOXIM IN PERITONEAL MACROPHAGES." In XIX INTERNATIONAL INTERDISCIPLINARY CONGRESS NEUROSCIENCE FOR MEDICINE AND PSYCHOLOGY. LCC MAKS Press, 2023. http://dx.doi.org/10.29003/m3312.sudak.ns2023-19/201-202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antiasthmatic agents' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography